A Study of the Safety and Efficacy of MK-3577 in Participants With Type 2 Diabetes Mellitus (MK-3577-009)
Status:
Terminated
Trial end date:
2010-07-13
Target enrollment:
Participant gender:
Summary
This study assessed the safety and efficacy of MK-3577. The primary efficacy hypothesis was
that, after 4 weeks of treatment, either the morning (AM) administration or the evening (PM)
administration of MK-3577 provides superior reduction of 24-hour weighted mean glucose (WMG)
levels compared to placebo (PLA). The primary safety hypothesis was that MK-3577 is well
tolerated compared to placebo.